Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0756
D

Failure to Monitor for Anticoagulant Complications

Norwalk, California Survey Completed on 07-25-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

A deficiency occurred when the facility failed to ensure that a licensed pharmacist performed appropriate monitoring for complications related to Xarelto, an anticoagulant medication, for one resident. The resident, who had a history of diabetes mellitus and atrial fibrillation, was admitted and readmitted to the facility and was assessed as having moderately impaired cognition and requiring substantial to maximal assistance with activities of daily living. The resident began receiving Xarelto 20 mg, but there was no evidence in the medical record that monitoring for adverse consequences, such as bleeding or bruising, was conducted as required by facility policy. During a review of the medication administration record and interviews with nursing staff, it was confirmed that monitoring for signs and symptoms of bleeding had not been initiated when the medication was started. The facility's policy specifically required daily monitoring for such complications with the administration of Xarelto, but this was not followed, as acknowledged by the licensed vocational nurse involved in the resident's care.

An unhandled error has occurred. Reload 🗙